Effects of Sacubitril/Valsartan combined with Bisoprolol in treatment of patients with acute heart failure
Objective:To observe effects of Sacubitril/Valsartan combined with Bisoprolol in treatment of patients with acute heart failure(AHF).Methods:A prospective study was conducted on 90 patients with AHF admitted to the hospital from January 2021 to June 2022.They were divided into control group and study group by using the random number table method,45 cases in each group.The control group was treated with Bisoprolol,while the study group was treated with Sacubitril/Valsartan on the basis of that of the control group.The clinical efficacy,the levels of cardiac function indexes[left ventricular ejection fraction(LVEF),cardiac index(CI),left atrial diameter(LAD)],the myocardial injury markers[cardiac troponin T(cTnT),N-terminal pro-B-type natriuretic peptide(NT-proBNP),homocysteine(Hcy)],the inflammatory factors[interleukin-1β(IL-1β),intercellular adhesion molecule-1(ICAM-1)],and the oxidative stress indexes[malondialdehyde(MDA),myeloperoxidase(MPO),superoxide dismutase(SOD)],and the incidence of adverse cardiovascular events(MACE)were compared between the two groups before and after the treatment.Results:The total effective rate of the study group was 93.33%(42/45),which was higher than 77.78%(35/45)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of LVEF and CI in the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group;the LAD levels of the two groups were lower than those before the treatment,and that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).The levels of NT-proBNP,cTnT and Hcy in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of IL-1β and ICAM-1 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The SOD levels of the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;the levels of MPO and MDA in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;and the differences were statistically significant(P<0.05).Further,the incidence of MACE in the study group was 4.54%,which was lower than 18.61%in the control group,the difference was statistically significant(P<0.05).Conclusions:Sacubitril/Valsartan combined with Bisoprolol in the treatment of the AHF patients can improve the total effective rate of treatment,improve the cardiac function indexes and oxidative stress indexes levels,and reduce the levels of myocardial injury markers,inflammatory factors and the incidence of MACE.Moreover,it is superior to single Bisoprolol treatment.
NETL
NSTL
万方数据
